Atlas Venture Associates XI’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

Atlas Venture Associates XI’s Portfolio SURF Stock Details SURF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$27.2M	Buy	+2,945,453	New	+$25.6M	4.31%	3

Other funds holding SURF

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Atlas Venture Associates XI's SURF Position: Q4 2020 in Review

Atlas Venture Associates XI opened a new position in Surface Oncology, Inc. Common Stock (SURF) in Q4 2020: 2,945,453 shares worth $27.2M. The stake represents 4.31% of the portfolio and ranks #3 among its holdings.

91 funds tracked by Wall St. Rank hold SURF as of Q4 2020.

Atlas Venture Associates XI held 2,945,453 shares of Surface Oncology, Inc. Common Stock worth $27.2M as of Q4 2020.
Surface Oncology, Inc. Common Stock was a new Atlas Venture Associates XI position in Q4 2020.
Surface Oncology, Inc. Common Stock made up 4.31% of Atlas Venture Associates XI's portfolio in Q4 2020, its #3 holding.
91 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q4 2020.

Based on Atlas Venture Associates XI's 13F filing for Q4 2020, filed 1 Feb 2021.